{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:30:46Z","timestamp":1776936646038,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the second Affiliated Hospital of Army Military Medical University Discipline Talent Construction Special Project","award":["2023XKRC007"],"award-info":[{"award-number":["2023XKRC007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-024-01663-w","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T01:17:32Z","timestamp":1734657452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence"],"prefix":"10.1186","volume":"24","author":[{"given":"Luo","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Shuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Qingjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Jingzhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-8420","authenticated-orcid":false,"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"5","key":"1663_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","volume":"2","author":"JS Joseph","year":"2019","unstructured":"Joseph JS, Lam V, Patel MI. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. European urology oncology. 2019;2(5):551\u201361. https:\/\/doi.org\/10.1016\/j.euo.2018.11.001.","journal-title":"European urology oncology"},{"key":"1663_CR2","doi-asserted-by":"publisher","unstructured":"Casado E, Borque-fernando A, Caama\u00f1o M, Gra\u00f1a J, Mu\u00f1oz-rodr\u00edguez J, Morote J. Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. The World Journal of Men's Health. 2022;40(1):74. https:\/\/doi.org\/10.5534\/wjmh.210061.","DOI":"10.5534\/wjmh.210061"},{"issue":"3","key":"1663_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/wvn.12094","volume":"12","author":"Z Munn","year":"2015","unstructured":"Munn Z, Lockwood C, Moola S. The Development and Use of Evidence Summaries for Point of Care Information Systems: A Streamlined Rapid Review Approach. Worldviews on evidence-based nursing. 2015;12(3):131\u20138. https:\/\/doi.org\/10.1111\/wvn.12094.","journal-title":"Worldviews on evidence-based nursing"},{"key":"1663_CR4","doi-asserted-by":"publisher","unstructured":"Zhu Z, Hu Y, Xing W, Zhou Y, Gu Y. Composition of the different types of evidence-based problems. Journal of Nurses Training,. 2017;32(21), 1991\u20131994. https:\/\/doi.org\/10.16821\/j.cnki.hsjx.2017.21.025.","DOI":"10.16821\/j.cnki.hsjx.2017.21.025"},{"issue":"4","key":"1663_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ebn.12.4.99-b","volume":"12","author":"A Dicenso","year":"2009","unstructured":"Dicenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. Evid Based Nurs. 2009;12(4):99\u2013101. https:\/\/doi.org\/10.1136\/ebn.12.4.99-b.","journal-title":"Evid Based Nurs"},{"issue":"18","key":"1663_CR6","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839\u201342. https:\/\/doi.org\/10.1503\/cmaj.090449.","journal-title":"CMAJ"},{"key":"1663_CR7","doi-asserted-by":"publisher","unstructured":"Gu Y, Zhang HW, Zhou YF et al. JBI Center for Evidence-Based Health Care Quality Evaluation Tool on Different Types of Research - Methodological Quality Evaluation of Systematic Evaluation. Journal of Nurse Advancement. (06),513\u2013516.https:\/\/doi.org\/10.16821\/j.cnki.hsjx.2018.06.0012.","DOI":"10.16821\/j.cnki.hsjx.2018.06.0012"},{"key":"1663_CR8","doi-asserted-by":"publisher","unstructured":"Wang QQ, Hu Y. JBI Evidence Pre Grading and Evidence Recommendation Level System (2014 Edition), J Journal of Nurse Continuing Education. 2015,30(11):964\u2013967. https:\/\/doi.org\/10.16821\/j.cnki.hsjx.2015.11.002.","DOI":"10.16821\/j.cnki.hsjx.2015.11.002"},{"key":"1663_CR9","unstructured":"Prostate Cancer, Version 3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Online: NCCN; 2024. https:\/\/www.nccn.org\/patients."},{"key":"1663_CR10","doi-asserted-by":"publisher","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, J L H van Leenders G, Liew, M, Linares Espinos E, Oldenburg J, van Oort IM,. ... Cornford P. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European urology. 2024;S0302\u20132838(24)02306\u20136. Advance online publication. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"1663_CR11","unstructured":"Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence (NICE); 2021.\u00a0https:\/\/www.nice.org.uk\/guidance\/ng131."},{"key":"1663_CR12","doi-asserted-by":"publisher","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2020 Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of oncology: official journal of the European Society for Medical Oncology 31 9 1119 1134https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"1663_CR13","doi-asserted-by":"publisher","unstructured":"Alibhai SMH, Zukotynski K, Walker-dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care \u2014 Cancer Care Ontario Clinical Practice Guideline.Clinical Oncology. 2017;29(6):348\u2013355.https:\/\/doi.org\/10.1016\/j.clon.2017.01.007.","DOI":"10.1016\/j.clon.2017.01.007"},{"key":"1663_CR14","doi-asserted-by":"publisher","unstructured":"Kakehi Y, Sugimoto M, Taoka R. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).International Journal of Urology. 2017;24(9):648\u2013666.https:\/\/doi.org\/10.1111\/iju.13380.","DOI":"10.1111\/iju.13380"},{"key":"1663_CR15","doi-asserted-by":"publisher","unstructured":"Joseph JS, Lam V, Patel MI. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.European Urology Oncology. 2019;2(5),551\u2013561.https:\/\/doi.org\/10.1016\/j.euo.2018.11.001.","DOI":"10.1016\/j.euo.2018.11.001"},{"issue":"4","key":"1663_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3760\/cma.j.cn112152-20240206-00067","volume":"46","author":"China Prostate Cancer Research Collaborative Group","year":"2024","unstructured":"China Prostate Cancer Research Collaborative Group. Chinese expert consensus on the follow-up management of drug depot therapy for prostate cancer (2024 edition)[J]. Chinese Journal of Oncology. 2024;46(4):285\u201395. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240206-00067.","journal-title":"Chinese Journal of Oncology"},{"key":"1663_CR17","doi-asserted-by":"publisher","unstructured":"Urological Health Promotion Branch of China Healthcare International Promotion and Exchange Society, Urology Committee of Chinese Society of Research Hospitals, Therapeutics Group of Chinese Society of Nuclear Medicine. Consensus on the safety of 223Ra nuclide therapy for bone metastatic desmoplasia-resistant prostate cancer[J]. Journal of Modern Urology. 2022,27(5):373\u2013380,385. https:\/\/doi.org\/10.3969\/j.issn.1009-8291.2022.05.002.","DOI":"10.3969\/j.issn.1009-8291.2022.05.002"},{"key":"1663_CR18","doi-asserted-by":"publisher","unstructured":"Casta\u00f1eda S , Casas A, Gonz\u00e1lez-del-alba A, Mart\u00ednez-d\u00edaz-guerra G, Nogu\u00e9s X, Thies CO, Suau \u00d3T, Rodr\u00edguez-lescure \u00c1. Bone loss induced by cancer treatments in breast and prostate cancer patients.Clinical and Translational Oncology. 2022;24(11):2090\u20132106.https:\/\/doi.org\/10.1007\/s12094-022-02872-1.","DOI":"10.1007\/s12094-022-02872-1"},{"key":"1663_CR19","doi-asserted-by":"publisher","unstructured":"Santini D, Berruti A, Maio MD, Procopio G, Bracarda S, Ibrahim T, Bertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open. 2020;5(2),e000652.https:\/\/doi.org\/10.1136\/esmoopen-2019-000652.","DOI":"10.1136\/esmoopen-2019-000652"},{"key":"1663_CR20","doi-asserted-by":"publisher","unstructured":"Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-coates L, Walsh JS, Mitchell C. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.Journal of Bone Oncology. 2020;25(),100311.https:\/\/doi.org\/10.1016\/j.jbo.2020.100311.","DOI":"10.1016\/j.jbo.2020.100311"},{"issue":"1","key":"1663_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics 2023[J]. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1663_CR22","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"HM Zeng","year":"2018","unstructured":"Zeng HM, Chen WQ, Zheng RS, et al. Changing cancersurvival in China during 2003\u201315: a pooled analysis of 17population-based cancer registries[J]. Lancet Glob Health. 2018;6(5):e555\u201367. https:\/\/doi.org\/10.1016\/S2214-109X(18)30127-X.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"1663_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/biomedicines9091247","volume":"9","author":"I Henr\u00edquez","year":"2021","unstructured":"Henr\u00edquez I, Roach M 3rd, Morgan TM, Bossi A, G\u00f3mez JA, Abuchaibe O, Cou\u00f1ago F. Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines. 2021;9(9):1247. https:\/\/doi.org\/10.3390\/biomedicines9091247.","journal-title":"Biomedicines"},{"key":"1663_CR24","doi-asserted-by":"publisher","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al Prostate cancer,version 4.2023, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2023, 21(10):1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","DOI":"10.6004\/jnccn.2023.0050"},{"issue":"1","key":"1663_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Cl\u00e9zardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L. Bone metastases Nature reviews Disease primers. 2020;6(1):83. https:\/\/doi.org\/10.1038\/s41572-020-00216-3.","journal-title":"Bone metastases Nature reviews Disease primers"},{"key":"1663_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur. Urol."},{"key":"1663_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Iverg\u00e5rd M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"1663_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00223-017-0369-x","volume":"102","author":"C Handforth","year":"2018","unstructured":"Handforth C, D\u2019Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018;102(2):251\u201364.","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"1663_CR29","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"31","key":"1663_CR30","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk:a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897\u2013903.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1663_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154\u201364.","journal-title":"N Engl J Med"},{"issue":"3","key":"1663_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500\u20134.","journal-title":"Urology"},{"key":"1663_CR33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/EDBK_201411","volume":"38","author":"T Bao","year":"2018","unstructured":"Bao T, Peppone LJ, Robinson P. Addressing the unintentional consequences of cancer therapy with novel integrative therapeutics. Am Soc Clin Oncol Educ Book. 2018;38:822\u20138.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1663_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galvao","year":"2008","unstructured":"Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shan-non T, Rowling C, Prince R. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"1663_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.urology.2010.11.024","volume":"77","author":"K Bylow","year":"2011","unstructured":"Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology. 2011;77(4):934\u201340.","journal-title":"Urology"},{"key":"1663_CR36","doi-asserted-by":"crossref","unstructured":"Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorti-coid-induced osteoporosis: an update on effects and management.J Allergy Clin Immunol. 2013;132(5):1019\u201330.","DOI":"10.1016\/j.jaci.2013.08.040"},{"key":"1663_CR37","doi-asserted-by":"publisher","unstructured":"Yerramshetty J, Kim D, Yeni YN. Increased Microstructural Variability is Associated With Decreased Structural Strength But With Increased Measures of Structural Ductility in Human Vertebrae.Journal of Biomechanical Engineering. 2009;131(9).https:\/\/doi.org\/10.1115\/1.3148473.","DOI":"10.1115\/1.3148473"},{"key":"1663_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.reuma.2018.09.004","volume":"15","author":"A Naranjo Hern\u00e1ndez","year":"2019","unstructured":"Naranjo Hern\u00e1ndez A, Del Campo D, Fontecha P, Aguado Ac\u00edn MP, Arboleya Rodr\u00edguez L, Casado Burgos E, Casta\u00f1eda S, et al. Recommendations by the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin (Engl Ed). 2019;15:188\u2013210.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.20.00434","volume":"38","author":"A Dalla Volta","year":"2020","unstructured":"Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, et al. Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol. 2020;38:3363\u20136.","journal-title":"J Clin Oncol"},{"key":"1663_CR40","doi-asserted-by":"publisher","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in canc-er patients: ESMO Clinical Practice Guidelines.Annals of Oncology. 2014;25(),iii124-iii137.https:\/\/doi.org\/10.1093\/annonc\/mdu103","DOI":"10.1093\/annonc\/mdu103"},{"key":"1663_CR41","unstructured":"Breast cancer: Guidelines for treatment of cancer by site.Version 5. National Comprehensive Cancer Network; 2021.\u00a0https:\/\/www.nccn.org\/guidelines\/category_1#site."},{"issue":"4","key":"1663_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventos CX. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99(4):812\u20135.","journal-title":"BJU Int"},{"issue":"2","key":"1663_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13679-021-00433-1","volume":"10","author":"I Karampela","year":"2021","unstructured":"Karampela I, Sakelliou A, Vallianou N, Christodoulatos GS, Magkos F, Dalamaga M. Vitamin D and obesity: current evidence and controversies. Curr Obes Rep. 2021;10(2):162\u201380.","journal-title":"Curr Obes Rep"},{"key":"1663_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-015-3399-0","volume":"27","author":"J Uth","year":"2016","unstructured":"Uth J, Hornstrup T, Christensen JF, et al. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Osteoporos Int. 2016;27:1507\u201318.","journal-title":"Osteoporos Int"},{"key":"1663_CR45","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant-prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379(9810):39e46.","DOI":"10.1016\/S0140-6736(11)61226-9"},{"key":"1663_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745\u201355.","journal-title":"N Engl J Med"},{"key":"1663_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3816\/CGC.2003.n.010","volume":"2","author":"LE Cereceda","year":"2003","unstructured":"Cereceda LE, et al. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer. 2003;2:34.","journal-title":"Clin Prostate Cancer"},{"key":"1663_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3171\/2009.1.SPINE08657","volume":"11","author":"KL Chaichana","year":"2009","unstructured":"Chaichana KL, et al. Outcome following decompressive surgery for different histological types of metastatic tumors causing epidural spinal cord compression. Clinical article J Neurosurg Spine. 2009;11:56.","journal-title":"Clinical article J Neurosurg Spine"},{"key":"1663_CR49","doi-asserted-by":"publisher","unstructured":"Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, et al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.\u00a0J Natl Cancer Inst. 2015;107(10): djv197. https:\/\/doi.org\/10.1093\/jnci\/djv197.","DOI":"10.1093\/jnci\/djv197"},{"key":"1663_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.spinee.2006.10.020","volume":"7","author":"BM Frankel","year":"2007","unstructured":"Frankel BM, et al. Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. Spine J. 2007;7:575.","journal-title":"Spine J"},{"key":"1663_CR51","first-page":"276","volume":"5","author":"J Dutka","year":"2003","unstructured":"Dutka J, et al. Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortop Traumatol Rehabil. 2003;5:276.","journal-title":"Ortop Traumatol Rehabil"},{"key":"1663_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1227\/01.NEU.0000290899.15567.68","volume":"61","author":"BM Frankel","year":"2007","unstructured":"Frankel BM, et al. Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery. 2007;61:531.","journal-title":"Neurosurgery."},{"key":"1663_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2018.78.1211","volume":"37","author":"AJ Lawton","year":"2019","unstructured":"Lawton AJ, et al. Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review. J Clin Oncol. 2019;37:61.","journal-title":"J Clin Oncol"},{"key":"1663_CR54","doi-asserted-by":"crossref","unstructured":"SARTOR O, DE BONO JS. Metastatic prostate cancer[J]. N Engl J Med. 2018;378(7):645 657.","DOI":"10.1056\/NEJMra1701695"},{"key":"1663_CR55","doi-asserted-by":"crossref","unstructured":"KRATOCHWIL C, HABERKORN U, GIESEL FL. Radionu clide therapy of metastatic prostate cancer. Semin Nucl Med. 2019,49(4):313\u2013325.","DOI":"10.1053\/j.semnuclmed.2019.02.003"},{"key":"1663_CR56","doi-asserted-by":"crossref","unstructured":"CURSANO MC, IULIANI M, CASADEI C, et a1. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review r-j]. Crit Rev Oncol Hemat01, 2020, 146: 102864.","DOI":"10.1016\/j.critrevonc.2020.102864"},{"key":"1663_CR57","doi-asserted-by":"crossref","unstructured":"DE VINCENTIS G, GERRITSEN W, GSCHWEND JE, et a1. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019,30(11):1728-1739.","DOI":"10.1093\/annonc\/mdz270"},{"issue":"3","key":"1663_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium\u4e00223 and survival in metastatic prostate cancer[J]. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"1663_CR59","doi-asserted-by":"crossref","unstructured":"PARKER C, FINKELSTEIN SE, MICHALSKI JM, et a1. Efficacy and safety of Radium\u2014223 dichloride in symptomatic castratlon-reslstant prostate cancer opioid use from the Phase 3 ALSYMPCA trial[J]. Eur Urol. 2016,70(5): 875\u2013883.","DOI":"10.1016\/j.eururo.2016.06.002"},{"key":"1663_CR60","doi-asserted-by":"crossref","unstructured":"VAN DER DOELEN MJ, MEHRA N, HERMSEN R, et a1. Patient selection for Radium-223 therapy in patients with bone metastatic castration\u2014resistant prostate cancer: new recommendations and future perspectives[J]. Clin Genitourin Cancer, 2019, 17(2): 79 87.","DOI":"10.1016\/j.clgc.2018.11.008"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01663-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01663-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01663-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T02:02:42Z","timestamp":1734660162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01663-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01663-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol, case record form, and informed consent form were reviewed by the Ethics Committee of the Second Affiliated Hospital of Army Medical University. Written informed consent was obtained from all participants before enrolment. The study was conducted in accordance with principles of the Declaration of Helsinki. Confidentiality of all the data was maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}